Im live2 free sex com

23-Aug-2017 20:31 by 5 Comments

Im live2 free sex com - deanna pappas who is she dating

Androgen-deprivation therapy, more commonly known as hormone therapy, is one of the most powerful weapons in the fight against prostate cancer because it significantly reduces the fuel supply that is feeding malignant growth.Hormone therapies now available target testosterone production by the testicles or androgen’s activity in the body.

We don’t know yet why men with prostate cancer develop androgen resistance, but a leading theory is that prostate tumors contain different types of cells, some of which are resistant to hormone treatment.

Androgens, the family of male sex hormones that includes testosterone, function as a fuel for growth — a quality that explains their central role in both normal development and prostate cancer.

In adolescent boys, androgens not only trigger sexual development, but also contribute to a deeper voice, a beard, and increased muscle strength and bone mass.

In fact, one of my patients has now been on some type of hormone therapy for nearly 16 years.

Once reserved solely as a treatment for metastatic prostate cancer, hormone therapy is now also used in a variety of other ways.

When prostate cancer develops, however, this androgen fuel contributes to tumor growth and progression.

About 90% to 95% of androgens are produced in the testicles, while another 5% to 10% are produced by the adrenal glands.However, in a review of four studies involving 2,167 men with metastatic prostate cancer, the Cochrane Collaboration (a prestigious international organization known for its independent analysis) concluded that early hormone therapy had offered only a small overall survival advantage over deferred treatment, and cautioned that more research on the issue needs to be done. Hormone therapy is sometimes given in conjunction with a definitive prostate cancer treatment, such as radiation therapy, in order to improve health outcomes. On the one hand, neoadjuvant hormone therapy is effective at “down-staging” the disease before surgery by shrinking the primary tumor and eradicating micrometastases.Although debate on this issue continues, in most cases I advise my patients with metastatic disease to begin hormone treatment early on. Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer. When hormone therapy is given in advance of a primary treatment, it’s known as neoadjuvant therapy; when it’s given during or after a primary treatment, it’s known as adjuvant therapy. Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer. Short-term studies were encouraging, showing that neoadjuvant hormone therapy reduced the risk of finding a positive margin in the excised tissue.This is particularly important for someone with spine metastases, because a bone fracture or extension of the cancer into the spinal cord area could lead to impaired mobility and even paralysis. (For more information about research in this area, see “Hormone therapy: Immediate versus delayed.”) 1997;5–46. A randomized controlled study involving 206 men with early-stage prostate cancer evaluated whether adding six months of hormone therapy to external-beam radiation treatment would boost both overall survival and disease-free survival (meaning that the men did not suffer a relapse). The same research group found, in an earlier study, that the addition of hormone therapy was of most benefit to men who were considered at moderate or high risk, based on their clinical profile. A number of studies have shown that men with early-stage prostate cancer are more likely to be cured when hormone therapy is given in conjunction with radiation therapy (see Table 2 above for the results of one study). On the other hand, long-term studies indicate that neoadjuvant hormone therapy does not extend time to biochemical recurrence or improve survival. Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockade in Clinical Stage B2 Prostate Cancer.Even when the disease is regionally advanced, meaning that it has progressed to tissues immediately surrounding the prostate gland, neoadjuvant hormone therapy reduces risk of progression and relapse (see “Evidence for combining hormone therapy and radiation treatment”). Long-Term Results with Immediate Androgen Suppression and External Irradiation in Patients with Locally Advanced Prostate Cancer (an EORTC Study): A Phase III Randomised Trial. (For examples of studies, see “Evidence about hormone therapy and prostatectomy.”) 2006; CD006019. The Lupron Depot Neoadjuvant Prostate Cancer Study.For example, one small but often-cited study, published in 1999 in the found that 77% of men who had prostate cancer with lymph node metastases and chose to undergo hormone therapy were still alive and had no recurrent disease roughly seven years later, as compared with only 18% of men who decided to forgo hormone treatment until the cancer spread to bones or lungs. Although we don’t understand this phenomenon completely, animal studies suggest that a dose of radiation is more effective at killing cancer cells when given in the setting of androgen deprivation.